Literature DB >> 24296865

Parkinson's disease mild cognitive impairment: application and validation of the criteria.

Gert J Geurtsen1, Jeroen Hoogland1, Jennifer G Goldman2, Ben A Schmand3, Alexander I Tröster4, David J Burn5, Irene Litvan6.   

Abstract

Dementia in Parkinson's disease (PD) is a serious health issue and a major concern for many patients. In most cases mild cognitive impairment (MCI) is considered a transitional stage between normal cognitive functioning and dementia which is of potential importance in the early identification of patients at risk for dementia. Recently, the Movement Disorder Society (MDS) proposed diagnostic criteria for MCI in PD (PD-MCI). These criteria comprise two operationalizations: Level I (based on an abbreviated assessment) and Level II (based on comprehensive neuropsychological evaluation permitting MCI subtyping). These criteria need to be validated. This paper describes a project aiming to validate the MDS PD-MCI criteria by pooling and analyzing cross-sectional and longitudinal neuropsychological databases comprising ≥5,500 PD patients and ≥1,700 controls. After applying the MDS PD-MCI Level I and Level II criteria, rates of conversion to PD-dementia and predictive variables for conversion to PD-dementia will be established. This study will also assist in identifying whether revisions of the PD-MCI criteria are required.

Entities:  

Keywords:  Parkinson disease; dementia; mild cognitive impairment; neuropsychological tests/standards; validation studies

Mesh:

Year:  2014        PMID: 24296865      PMCID: PMC4380013          DOI: 10.3233/JPD-130304

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  24 in total

1.  Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease.

Authors:  Jennifer G Goldman; Samantha Holden; Bryan Bernard; Bichun Ouyang; Christopher G Goetz; Glenn T Stebbins
Journal:  Mov Disord       Date:  2013-10-09       Impact factor: 10.338

Review 2.  MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

Authors:  Irene Litvan; Dag Aarsland; Charles H Adler; Jennifer G Goldman; Jaime Kulisevsky; Brit Mollenhauer; Maria C Rodriguez-Oroz; Alexander I Tröster; Daniel Weintraub
Journal:  Mov Disord       Date:  2011-06-09       Impact factor: 10.338

3.  How precise are activities of daily living scales for the diagnosis of Parkinson's disease dementia? A pilot study.

Authors:  Josephine B M Christ; Monika Fruhmann Berger; Ellen Riedl; Deborah Prakash; Ilona Csoti; Wolfgang Molt; Susanne Gräber; Kathrin Brockmann; Daniela Berg; Inga Liepelt-Scarfone
Journal:  Parkinsonism Relat Disord       Date:  2012-12-08       Impact factor: 4.891

4.  Cognitive change in newly-diagnosed patients with Parkinson's disease: a 5-year follow-up study.

Authors:  Mark Broeders; Daan C Velseboer; Rob de Bie; Johannes D Speelman; Dino Muslimovic; Bart Post; Rob de Haan; Ben Schmand
Journal:  J Int Neuropsychol Soc       Date:  2013-04-02       Impact factor: 2.892

5.  Measuring mild cognitive impairment in patients with Parkinson's disease.

Authors:  Connie Marras; Melissa J Armstrong; Christopher A Meaney; Susan Fox; Brandon Rothberg; William Reginold; David F Tang-Wai; David Gill; Paul J Eslinger; Cindy Zadikoff; Nancy Kennedy; Fred J Marshall; Mark Mapstone; Kelvin L Chou; Carol Persad; Irene Litvan; Benjamin T Mast; Adam T Gerstenecker; Sandra Weintraub; Sarah Duff-Canning
Journal:  Mov Disord       Date:  2013-03-20       Impact factor: 10.338

6.  Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study.

Authors:  Kenn Freddy Pedersen; Jan Petter Larsen; Ole-Bjorn Tysnes; Guido Alves
Journal:  JAMA Neurol       Date:  2013-05       Impact factor: 18.302

7.  Cognitive function in early Parkinson's disease: a population-based study.

Authors:  E Elgh; M Domellöf; J Linder; M Edström; H Stenlund; L Forsgren
Journal:  Eur J Neurol       Date:  2009-06-15       Impact factor: 6.089

8.  Cognitive decline in Parkinson's disease: a prospective longitudinal study.

Authors:  Dino Muslimović; Bart Post; Johannes D Speelman; Rob J De Haan; Ben Schmand
Journal:  J Int Neuropsychol Soc       Date:  2009-05       Impact factor: 2.892

9.  Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study.

Authors:  D Aarsland; K Brønnick; J P Larsen; O B Tysnes; G Alves
Journal:  Neurology       Date:  2008-11-19       Impact factor: 9.910

Review 10.  Mild cognitive impairment in Parkinson's disease.

Authors:  Alison Jane Yarnall; Lynn Rochester; David John Burn
Journal:  Age Ageing       Date:  2013-07-17       Impact factor: 10.668

View more
  24 in total

Review 1.  Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.

Authors:  Jennifer G Goldman; Neelum T Aggarwal; Cynthia D Schroeder
Journal:  Neurodegener Dis Manag       Date:  2015-10-30

Review 2.  Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests.

Authors:  Jeroen Hoogland; Lennard L van Wanrooij; Judith A Boel; Jennifer G Goldman; Glenn T Stebbins; John C Dalrymple-Alford; Connie Marras; Charles H Adler; Carme Junque; Kenn F Pedersen; Brit Mollenhauer; Cyrus P Zabetian; Paul J Eslinger; Simon J G Lewis; Ruey-Meei Wu; Martin Klein; Maria C Rodriguez-Oroz; Davide M Cammisuli; Paolo Barone; Roberta Biundo; Rob M A de Bie; Ben A Schmand; Alexander I Tröster; David J Burn; Irene Litvan; J Vincent Filoteo; Gert J Geurtsen; Daniel Weintraub
Journal:  Mov Disord       Date:  2018-09-14       Impact factor: 10.338

3.  Association of arterial stiffness with cognition in patients with Lewy body disorder.

Authors:  Dong-Woo Ryu; Joong-Seok Kim; Jee-Eun Lee; Jeong-Wook Park; Yoon-Sang Oh; Jae-Young An; Kwang-Soo Lee
Journal:  Neurol Sci       Date:  2017-05-05       Impact factor: 3.307

4.  Onset of Mild Cognitive Impairment in Parkinson Disease.

Authors:  David K Johnson; Zachary Langford; Mauricio Garnier-Villarreal; John C Morris; James E Galvin
Journal:  Alzheimer Dis Assoc Disord       Date:  2016 Apr-Jun       Impact factor: 2.703

Review 5.  Precision Medicine: Clarity for the Complexity of Dementia.

Authors:  Brenna Cholerton; Eric B Larson; Joseph F Quinn; Cyrus P Zabetian; Ignacio F Mata; C Dirk Keene; Margaret Flanagan; Paul K Crane; Thomas J Grabowski; Kathleen S Montine; Thomas J Montine
Journal:  Am J Pathol       Date:  2015-12-24       Impact factor: 4.307

6.  Elevated rates of mild cognitive impairment in HIV disease.

Authors:  David P Sheppard; Jennifer E Iudicello; Mark W Bondi; Katie L Doyle; Erin E Morgan; Paul J Massman; Paul E Gilbert; Steven Paul Woods
Journal:  J Neurovirol       Date:  2015-07-03       Impact factor: 2.643

7.  Evaluation of mild cognitive impairment subtypes in Parkinson's disease.

Authors:  Brenna A Cholerton; Cyrus P Zabetian; Jia Y Wan; Thomas J Montine; Joseph F Quinn; Ignacio F Mata; Kathryn A Chung; Amie Peterson; Alberto J Espay; Fredy J Revilla; Johnna Devoto; G Stennis Watson; Shu-Ching Hu; James B Leverenz; Karen L Edwards
Journal:  Mov Disord       Date:  2014-04-07       Impact factor: 10.338

8.  Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests?

Authors:  Jennifer G Goldman; Samantha Holden; Bichun Ouyang; Bryan Bernard; Christopher G Goetz; Glenn T Stebbins
Journal:  Mov Disord       Date:  2014-12-01       Impact factor: 10.338

Review 9.  Aging with HIV-1 Infection: Motor Functions, Cognition, and Attention--A Comparison with Parkinson's Disease.

Authors:  S DeVaughn; E M Müller-Oehring; B Markey; H M Brontë-Stewart; T Schulte
Journal:  Neuropsychol Rev       Date:  2015-11-17       Impact factor: 7.444

Review 10.  Widespread sex dimorphism in aging and age-related diseases.

Authors:  Nirmal K Sampathkumar; Juan I Bravo; Yilin Chen; Prakroothi S Danthi; Erin K Donahue; Rochelle W Lai; Ryan Lu; Lewis T Randall; Nika Vinson; Bérénice A Benayoun
Journal:  Hum Genet       Date:  2019-11-01       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.